Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study - Wikidata - awgldk - TriplyDB

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

http://www.wikidata.org/entity/Q28660706

about

Current and emerging treatment options in the management of lupus Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implications Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research Current and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis)Regulation of B lymphocytes and plasma cells by innate immune mechanisms and stromal cells in rheumatoid arthritis.Patient-reported outcomes in lupus clinical trials with biologics.Failure of a systemic lupus erythematosus response index developed from clinical trial data: lessons examined and learned.Efficacy of abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease.Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.Rationale for B cell targeting in SLE Current status of lupus nephritis.Belimumab for the treatment of systemic lupus erythematosus.Which outcome measures in SLE clinical trials best reflect medical judgment?Immunosuppressive Medications.In-/off-label use of biologic therapy in systemic lupus erythematosus.Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.Definition and initial validation of a Lupus Low Disease Activity State (LLDAS).Impact of standard of care treatments and disease variables on outcomes in systemic lupus erythematosus trials: analysis from the Lupus Foundation of America Collective Data Analysis Initiative Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2 Internalization of rituximab and the efficiency of B Cell depletion in rheumatoid arthritis and systemic lupus erythematosus Sensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus.Drugs in early clinical development for Systemic Lupus Erythematosus.Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus Lupus clinical development: will belimumab's approval catalyse a new paradigm for SLE drug development?Systemic lupus erythematosus: a therapeutic challenge for the XXI century.Update on B-cell targeted therapies for systemic lupus erythematosus.Emerging biological therapies for systemic lupus erythematosus.CD22 and Siglec-G regulate inhibition of B-cell signaling by sialic acid ligand binding and control B-cell tolerance.The need to define treatment goals for systemic lupus erythematosus.Biologics in systemic lupus erythematosus: current options and future perspectives.Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus.Evaluation of epratuzumab as a biologic therapy in systemic lupus erythematosus.Biologicals for the treatment of systemic lupus erythematosus: current status and emerging therapies.Progress with the use of monoclonal antibodies for the treatment of systemic lupus erythematosus.Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis.

P2860

Q26741266-AB88AAB8-96B5-48CD-851E-522D305F9034 Q26775756-E4B8F6CB-CE74-4015-BF50-E3DCCD2F5BD4 Q26799223-3A30B442-4545-4D11-8493-CF92A9EF5D5D Q27025692-D633E49B-B8F7-4DC7-B0F5-A7DB1D698998 Q27686770-B3B8AB15-ADC6-4AE6-A15C-EAE087814E01 Q30391564-D27B4040-3624-463F-8E10-3086D6C8DA85 Q31160251-BADA9E36-A627-4D8C-B8DD-870D98B631BD Q33431030-EF9C2215-9E0F-4E69-8F4E-27B804578AE1 Q33691812-BA8AF3B4-8E5A-471F-80AA-8653425E7266 Q33731705-0C991D91-F9E6-4F5E-985F-1E3C00C1868F Q33829700-BA435A64-758F-4AFD-943F-90A870051859 Q33882751-4F7DEB1A-7083-4190-9CD4-D91FF4B1EB78 Q34455827-0E75355B-8556-4748-ABF1-DAA27221ECDE Q34478866-6D49400B-FB71-4726-9181-24FDB5F769D3 Q34484801-D57C759F-2855-4536-A0CE-0DD5B0641F82 Q35094536-611A83C3-DC09-4186-9E0B-D780A72688E7 Q35170984-CEA7F383-5A7E-4148-8957-F6D9549B7956 Q35309470-72DEF1FC-B8F0-4FEE-8840-9CCA711FF0A2 Q35761089-C033055F-3B92-40D7-8F5F-BB0FF5F8E8BE Q35803646-6FB7215F-E781-40F9-95DB-7BD4BE83A840 Q36154537-F53EF7E7-0D99-401D-8DB3-09338EFFDE45 Q36430066-CF34DED7-0251-47D9-BD40-DAF380D16B90 Q36532571-6F9E20D7-3405-4CCD-AABB-FBF95898A157 Q37316490-604028BF-2677-4D91-B238-7F60C9C10354 Q37324772-0C920154-2056-453D-8FA5-954E5B811038 Q37398870-C0FA8F63-D33D-4822-8C67-0552BFF2A590 Q37633396-4472DE72-5BE8-43F7-8756-B664EB599978 Q37633408-C3A05C7D-C619-4F9E-A20A-1954D0E29E8E Q38184585-1DBC8B6C-D4F1-4647-B6BD-17A7B65B3F62 Q38191835-A8C0790F-1731-44C3-AD04-297447DCE7B1 Q38192656-88058B5B-96D9-4AA8-929C-F8096B9E5C14 Q38192683-BD9D32A8-E9D7-4120-B976-4B754C73558E Q38227144-075CBC25-1E80-4358-9225-27D16EA08510 Q38232471-E8C21003-D4FA-4D62-B15A-66681FE19D45 Q38238798-DAB416E5-0FAE-40BA-8EF2-086AAB9B8B24 Q38271939-6E267400-06BF-4315-AAB4-29935F8AFCCA Q38286372-72D90B2E-4405-4B77-A270-144E62E148B5 Q38289398-F931FEA4-2B6D-4D92-B0A1-E3D312EE4F20 Q38389307-49DE04C8-B579-4F8B-A72F-BD45E93AEE1B Q38408710-E44ABE80-A500-4737-A38A-5F9656AFAD35

P2860

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

http://www.wikidata.org/entity/Q28660706

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Efficacy and safety of epratuz ...... -controlled, multicentre study

@ast

Efficacy and safety of epratuz ...... -controlled, multicentre study

@en

Efficacy and safety of epratuz ...... -controlled, multicentre study

@nl

type

label

Efficacy and safety of epratuz ...... -controlled, multicentre study

@ast

Efficacy and safety of epratuz ...... -controlled, multicentre study

@en

Efficacy and safety of epratuz ...... -controlled, multicentre study

@nl

prefLabel

Efficacy and safety of epratuz ...... -controlled, multicentre study

@ast

Efficacy and safety of epratuz ...... -controlled, multicentre study

@en

Efficacy and safety of epratuz ...... -controlled, multicentre study

@nl

P1433

Q28660706-53DF9384-F125-4654-9770-6959851EE1BD

P1476

Q28660706-6D908ACE-A3A0-4F14-8BE5-29089DD21389

P2093

Q28660706-14CDB11E-7320-41D5-8CCE-CAD5CDC4F4B2

Q28660706-45BBF5D1-85D8-4022-94D4-C94BA2CE556C

Q28660706-57AA9F2D-5644-4C92-BA13-0D8818CB52BF

Q28660706-60F72E77-3B43-4342-A302-8C39907326E0

Q28660706-7587A7C3-8B34-4A99-9BF7-38A94367F7A6

Q28660706-B1E011D7-6FD9-4321-A975-403C499ACE2B

Q28660706-D1ED9727-F55D-444B-A97C-CBF6FD71048D

Q28660706-F5F4A1DB-F8CB-4841-9851-EE0C1BB6BF14

Q28660706-F9D095E1-E523-44E7-ADB4-2D381896E1AD

P2860

Q28660706-025567FF-70C0-4690-85A6-498B1041FE85

Q28660706-061DA3E2-D60A-4E6F-8B49-47BD48A36989

Q28660706-100CA1E1-5B5F-4CBF-BEB3-99361E9EB24F

Q28660706-1155CDE2-8400-45F6-A057-979D9EEF9565

Q28660706-14BA04E8-369C-4139-8E5B-5D067E77482D

Q28660706-15D6BF54-491A-4E67-B497-26412C02BFF0

Q28660706-18AE77CA-C099-4236-B55C-0C49A75D1C8B

Q28660706-2001799E-E499-405F-BF35-9DAAD09BB570

Q28660706-27026D2A-A26D-4F8D-9F65-43FC8B18CD30

Q28660706-27CC860C-8108-4D84-AE28-1917C57903F7

P304

Q28660706-83A545D5-3CA9-4015-994C-5D649A8D35B0

P31

Q28660706-B7281A56-F6EC-4FB2-B2CD-6BD8A800EF89

P3181

Q28660706-21510DB4-9770-4177-A82A-E168243B4795

P356

Q28660706-5FDE4A44-F338-402D-AE95-C90DD1FF4EE2

P407

Q28660706-554A4B77-FD0F-4493-B23D-4C469A91B16B

P433

Q28660706-6A26E27E-15DA-4917-866E-8B0784296B9B

P478

Q28660706-FD97D2D2-2AEA-437C-82D3-D486EF97B7EE

P50

Q28660706-29FAB1BE-ED0D-4022-807B-D4487D450D42

Q28660706-9FC2E507-242C-4A70-8E3F-F2F221B914D2

P577

Q28660706-F336DFB5-6805-4DDA-8F0D-25593ACD14A4

P5875

Q28660706-08DA192F-46EB-4AB6-B5AE-326853A79F73

P698

Q28660706-6359071A-4009-4D4E-9A7F-FBECDE41FAE3

P921

Q28660706-27E8D2AF-379D-4DC3-BDFA-23944822E076

Q28660706-6B57A6A2-43E9-47A5-8535-AAF986FF5944

Q28660706-F3F05197-49D7-494D-A695-229B281839E4

P932

Q28660706-D5C6532B-A6E0-4D18-9AC9-3BFEA8950F5A

P3181

P356

ANNRHEUMDIS-2012-202760

P1433

Annals of the Rheumatic Diseases

P1476

Efficacy and safety of epratuz ...... -controlled, multicentre study

@en

P2093

Anna Barry

http://www.w3.org/2001/XMLSchema#string

Brian Kilgallen

http://www.w3.org/2001/XMLSchema#string

Daniel J Wallace

http://www.w3.org/2001/XMLSchema#string

Frederic A Houssiau

http://www.w3.org/2001/XMLSchema#string

Kenneth Kalunian

http://www.w3.org/2001/XMLSchema#string

Lexy Kelley

http://www.w3.org/2001/XMLSchema#string

Marilyn Pike

http://www.w3.org/2001/XMLSchema#string

Sabine Bongardt

http://www.w3.org/2001/XMLSchema#string

Vibeke Strand

http://www.w3.org/2001/XMLSchema#string

P2860

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Understanding the epidemiology and progression of systemic lupus erythematosus

Numerical scoring for the BILAG-2004 index

Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus.

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

Epratuzumab: targeting B-cell malignancies through CD22.

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.

B-cell targeting: a novel approach to immune intervention today and tomorrow.

British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus.

P304

183-90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

5084348

http://www.w3.org/2001/XMLSchema#string

P356

10.1136/ANNRHEUMDIS-2012-202760

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

73

http://www.w3.org/2001/XMLSchema#string

P50

Caroline Gordon

Michelle A. Petri

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234122973

http://www.w3.org/2001/XMLSchema#string

P698

23313811

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

3888603

http://www.w3.org/2001/XMLSchema#string